StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PHAT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $12.63 | $13.05 | +3.33% | 1.7M |
| 05-15 | $12.81 | $11.87 | -7.34% | 1.1M |
| 05-18 | $12.00 | $11.39 | -5.08% | 1.3M |
| 05-19 | $11.26 | $11.40 | +1.24% | 1.0M |
| 05-20 | $11.65 | $11.87 | +1.89% | 1.0M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $58.30M | $175.11M | $117.53M | $68.02M |
Operating Income | $-15.48M | $-159.99M | $-154.06M | $-138.79M |
Net Income | $-30.37M | $-221.25M | $-200.10M | $-75.81M |
EPS (Diluted) | $-0.37 | $-3.03 | $-2.76 | $-2.36 |
Total Assets | $305.12M | $259.15M | $240.29M | $250.22M |
Total Liabilities | $642.08M | $697.32M | $662.82M | $656.05M |
Cash & Equivalents | $180.90M | $129.97M | $135.16M | $149.57M |
Free Cash Flow OCF − CapEx | $-15.71M | $-167.00M | $-161.92M | $-147.77M |
Shares Outstanding | 79.44M | 71.42M | 71.04M | 70.10M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.